SEOUL -- Celltrion, a bio firm in South Korea, will develop a pen-type insulin biosimilar. It has yet to decide which products will be used as an original medicine.
Celltrion will be in charge of clinical trials and the development of an insulin biosimilar, while Poonglim Pharmatech, a domestic medical device manufacturer, will develop an automatic free-field pen-type injection. The two companies were selected for a state project supervised by the state-run Korea Evaluation Institute of Industrial Technology (KEIT) to develop customized diagnostic treatment products.
Pen injectors are designed for multiple doses, prefilled syringes, and autoinjectors. They typically use a cartridge system coupled with a multiuse formulation. An insulin pen is used to inject insulin for the treatment of diabetes. It is composed of an insulin cartridge and a dial to measure the dose, and is used with disposable pen needles to deliver the dose.
Celltrion is known for Remsima SC, the subcutaneous injection of Remsima, a copy of Janssen Biotech's Remicade treating rheumatoid arthritis and Crohn's disease. With Remsima SC, Celltrion has adopted an aggressive strategy to secure profitability and price penetration in competition with other subcutaneous-type products.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.